Ask about outcomes data and whether a peptide is FDA-approved. Anecdotes, he says, are not enough
MECHANISM CATEGORIES RESEARCH CONDITIONS SAFETY Side effects Limited human safety data Animal studies report wide therapeutic window Known interactions Methyl-donor depletion theoretical with chronic dosing (NNMT methylates nicotinamide using SAM) Contraindications Pregnancy/lactation (unstudied) REGULATORY STATUS FDA Not FDA-approved
December 5 Product: Merus Bizengri Indication: Pancreatic adenocarcinoma and non-small cell lung cancer with NGR1 mutations Merus bispecific antibody zenocutuzumab on Wednesday became the first and only therapy for advanced unresectable or metastatic pancreatic adenocarcinoma and NSCLC with NRG1 gene fusions
References 1 Int J Biochem Cell Biol Des(1-3)IGF-I: a truncated form of insulin-like growth factor-I (Ballard et al., 1996)Review describing des(1-3)IGF-I: the N-terminal Gly-Pro-Glu is absent, it binds IGF-binding proteins poorly, and it is generally ~10-fold more potent than IGF-I at stimulating cell hypertrophy and proliferation
states and internationally, including Canada, Europe, Australia, and other regions
Non-responders concluded study participation at 14 weeks
